INSYS Therapeutics (INSY) Bullish View Reiterated at Piper Jaffray Following Favorable Buprenorphine Data

August 24, 2016 3:59 PM EDT
Get Alerts INSY Hot Sheet
Price: $10.18 -6%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 5 | Down: 9 | New: 6
Trade INSY Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $28 price target on INSYS Therapeutics (NASDAQ: INSY) reported positive top-line results from a Phase III trial evaluating its sublingual spray form of buprenorphine for post-operative pain following bunionectomy surgery.

Amsellem commented, "We continue to believe that the product is a promising shot-on-goal not only in acute pain settings (e.g., emergency medicine, post-operative pain) but also in chronic pain (particularly considering that the molecule is uniquely positioned versus other opioids as less abuse-prone schedule III controlled substance). We believe INSY is well-positioned to deliver a long-term EPS CAGR (2017+) of at least in 25%-30%, and this only reflects contribution from Subsys and Syndros (which is set to launch later this year). This translates into an attractive risk/reward profile in the context of a 2017E P/E of 17x."

For an analyst ratings summary and ratings history on INSYS Therapeutics click here. For more ratings news on INSYS Therapeutics click here.

Shares of INSYS Therapeutics closed at $16.37 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Piper Jaffray

Add Your Comment